<p>Nuveen Asset Management LLC 在最近向證券交易委員會的披露中表示，在第四季度將其在 PROCEPT BioRobotics Co. (NASDAQ:PRCT - 免費報告) 的持股減少了 38.1%。該公司在季度內出售了 94,827 股後，持有 153,802 股該公司的股票。截至其最近的 SEC 文件，Nuveen Asset Management LLC 持有的 PROCEPT BioRobotics 的股份約佔 0.29%，價值 12,384,000 美元。</p>
<p>獲取 <strong>PROCEPT BioRobotics</strong> 的提醒：</p>
<ul>
<li>PROCEPT BioRobotics 是外科機器人領域的下一個重大突破嗎？</li>
</ul>
<p>其他幾家機構投資者也調整了他們在 PRCT 的持股。FMR LLC 在第四季度將其在 PROCEPT BioRobotics 的股份增加了 11.9%。FMR LLC 現在擁有 8,159,208 股該公司的股票，價值 656,979,000 美元，在此期間又購買了 866,328 股。Wellington Management Group LLP 在第四季度將其在 PROCEPT BioRobotics 的股份增加了 38.8%。Wellington Management Group LLP 現在擁有 1,490,952 股該公司的股票，價值 120,051,000 美元，在上個季度又購買了 416,819 股。Vanguard Group Inc. 在第四季度將其在 PROCEPT BioRobotics 的股份增加了 6.1%。Vanguard Group Inc. 現在擁有 5,140,426 股該公司的股票，價值 413,907,000 美元，在上個季度又購買了 297,075 股。Renaissance Technologies LLC 在第四季度購買了 PROCEPT BioRobotics 的新頭寸，價值約 22,422,000 美元。最後，Allspring Global Investments Holdings LLC 在第四季度將其在 PROCEPT BioRobotics 的股份增加了 218.1%。Allspring Global Investments Holdings LLC 現在擁有 401,210 股該公司的股票，價值 33,350,000 美元，在上個季度又購買了 275,071 股。機構投資者和對沖基金持有該公司 89.46% 的股份。</p>
<h2>內部活動</h2>
<p>在相關消息中，首席財務官 Kevin Waters 於 3 月 18 日星期二出售了 733 股該公司的股票。股票以平均價格 57.06 美元出售，總交易額為 41,824.98 美元。出售後，首席財務官現在直接持有 107,991 股該公司的股票，價值 6,161,966.46 美元。這代表其持股減少了 0.67%。該交易在向證券交易委員會的文件中披露，可以通過此鏈接訪問。此外，首席執行官 Reza Zadno 於 3 月 18 日星期二出售了 5,475 股該公司的股票。股票以平均價格 57.06 美元出售，總交易額為 312,403.50 美元。出售後，首席執行官現在直接持有 173,070 股該公司的股票，價值約 9,875,374.20 美元。該交易使其持股減少了 3.07%。該交易的披露可以在這裏找到。在過去三個月中，內部人士出售了價值 368,322 美元的 6,455 股公司股票。公司內部人士持有該公司 6.60% 的股份。</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>為什麼 Intuitive Surgical 股票在醫療行業中佔據主導地位</li>
</ul>
<p>幾位股票分析師最近對該股票發表了看法。Truist Financial 將 PROCEPT BioRobotics 的股票目標價從 90.00 美元下調至 70.00 美元，並在 4 月 11 日的研究報告中給予該股票 &#34;買入&#34; 評級。美國銀行將 PROCEPT BioRobotics 的股票目標價從 104.00 美元下調至 84.00 美元，並在 4 月 25 日的研究報告中給予該股票 &#34;買入&#34; 評級。Wall Street Zen 在週六的研究報告中將 PROCEPT BioRobotics 的股票評級從 &#34;賣出&#34; 上調至 &#34;持有&#34;。最後，摩根士丹利在 2 月 26 日的研究報告中將 PROCEPT BioRobotics 的股票目標價從 105.00 美元下調至 95.00 美元，並給予該股票 &#34;增持&#34; 評級。兩位分析師對該股票給予了持有評級，六位分析師給予了買入評級。根據 MarketBeat 的數據，該股票的共識評級為 &#34;適度買入&#34;，共識目標價為 90.00 美元。</p>
<p><strong>查看我們關於 PROCEPT BioRobotics 的最新報告</strong></p>
<h2>PROCEPT BioRobotics 股票表現</h2>
<p>NASDAQ:PRCT 週二開盤價為 57.38 美元。該公司的 50 日移動平均線為 55.27 美元，200 日移動平均線為 70.16 美元。該公司的市值為 31.7 億美元，市盈率為 -29.43，貝塔係數為 1.10。PROCEPT BioRobotics Co. 的一年低點為 47.04 美元，一年高點為 103.81 美元。該公司的債務與股本比率為 0.21，流動比率為 6.02，速動比率為 5.07。</p>
<p>PROCEPT BioRobotics (NASDAQ:PRCT - 獲取免費報告) 最近於 4 月 24 日星期四發佈了季度財報。該公司報告季度每股收益（EPS）為 -0.45 美元，超出分析師的共識預期（-0.49 美元）0.04 美元。該業務的季度收入為 6916 萬美元，而共識預期為 6539 萬美元。PROCEPT BioRobotics 的淨利潤率為 -50.07%，股本回報率為 -38.57%。該業務的收入同比增長 55.5%。在去年同期，該公司每股收益為 -0.51 美元。分析師預測 PROCEPT BioRobotics Co. 今年將發佈 -1.75 美元的每股收益。</p>
<h2>關於 PROCEPT BioRobotics</h2>
<p>(免費報告)</p>
<p>PROCEPT BioRobotics Corporation 是一家外科機器人公司，專注於在美國和國際上開發變革性泌尿學解決方案。該公司開發、製造和銷售 AquaBeam 機器人系統，這是一種圖像引導的外科機器人系統，旨在用於微創泌尿外科手術，重點治療良性前列腺增生 (BPH)。</p>
<h2>特色故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 PROCEPT BioRobotics</li>
<li>如何計算通貨膨脹率</li>
<li>Workday 股票價格暴跌：對 AI 投資者來説是自動買入</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>MercadoLibre 正在飆升——你應該等待更好的入場時機嗎？</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>對市場有疑慮？三隻股票幫助你度過恐懼、不確定性和懷疑</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 PROCEPT BioRobotics 嗎？</h2>
<p>在考慮 PROCEPT BioRobotics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在買入的股票，以便在更廣泛的市場注意到之前... 而 PROCEPT BioRobotics 並不在名單上。</p>
<p>雖然 PROCEPT BioRobotics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>在這裏查看這五隻股票</p>

PRCT

<p>Nuveen Asset Management LLC 在第四季度將其在 PROCEPT BioRobotics Co. (NASDAQ:PRCT) 的持股減少了 38.1%，目前持有 153,802 股，價值 1238 萬美元。其他機構投資者，包括 FMR LLC 和 Wellington Management，增加了他們的持股。內部人士的銷售包括首席財務官 Kevin Waters 和首席執行官 Reza Zadno 的股票出售。分析師的評級不一，目標價格範圍在 70 美元到 95 美元之間。該股票開盤價為 57.38 美元，市值為 31.7 億美元，市場共識評級為 “適度買入”</p>

<p>Nuveen Asset Management LLC decreased its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 38.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 153,802 shares of the company's stock after selling 94,827 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.29% of PROCEPT BioRobotics worth $12,384,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Nuveen Asset Management LLC 在最近向證券交易委員會的披露中表示，在第四季度將其在 PROCEPT BioRobotics Co. (NASDAQ:PRCT - 免費報告) 的持股減少了 38.1%。該公司在季度內出售了 94,827 股後，持有 153,802 股該公司的股票。截至其最近的 SEC 文件，Nuveen Asset Management LLC 持有的 PROCEPT BioRobotics 的股份約佔 0.29%，價值 12,384,000 美元。</p>
</div><p>Get <strong>PROCEPT BioRobotics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>PROCEPT BioRobotics</strong> 的提醒：</p>
</div><ul>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
</ul>
<div class="lb-trans"><ul>
<li>PROCEPT BioRobotics 是外科機器人領域的下一個重大突破嗎？</li>
</ul>
</div><p>Several other institutional investors have also modified their holdings of PRCT. FMR LLC grew its position in shares of PROCEPT BioRobotics by 11.9% in the fourth quarter. FMR LLC now owns 8,159,208 shares of the company's stock valued at $656,979,000 after purchasing an additional 866,328 shares during the period. Wellington Management Group LLP lifted its stake in shares of PROCEPT BioRobotics by 38.8% in the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after buying an additional 416,819 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of PROCEPT BioRobotics by 6.1% in the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after buying an additional 297,075 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of PROCEPT BioRobotics in the fourth quarter worth about $22,422,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of PROCEPT BioRobotics by 218.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 401,210 shares of the company's stock worth $33,350,000 after buying an additional 275,071 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者也調整了他們在 PRCT 的持股。FMR LLC 在第四季度將其在 PROCEPT BioRobotics 的股份增加了 11.9%。FMR LLC 現在擁有 8,159,208 股該公司的股票，價值 656,979,000 美元，在此期間又購買了 866,328 股。Wellington Management Group LLP 在第四季度將其在 PROCEPT BioRobotics 的股份增加了 38.8%。Wellington Management Group LLP 現在擁有 1,490,952 股該公司的股票，價值 120,051,000 美元，在上個季度又購買了 416,819 股。Vanguard Group Inc. 在第四季度將其在 PROCEPT BioRobotics 的股份增加了 6.1%。Vanguard Group Inc. 現在擁有 5,140,426 股該公司的股票，價值 413,907,000 美元，在上個季度又購買了 297,075 股。Renaissance Technologies LLC 在第四季度購買了 PROCEPT BioRobotics 的新頭寸，價值約 22,422,000 美元。最後，Allspring Global Investments Holdings LLC 在第四季度將其在 PROCEPT BioRobotics 的股份增加了 218.1%。Allspring Global Investments Holdings LLC 現在擁有 401,210 股該公司的股票，價值 33,350,000 美元，在上個季度又購買了 275,071 股。機構投資者和對沖基金持有該公司 89.46% 的股份。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In related news, CFO Kevin Waters sold 733 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the sale, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at $6,161,966.46. This represents a 0.67% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,455 shares of company stock valued at $368,322. Company insiders own 6.60% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Kevin Waters 於 3 月 18 日星期二出售了 733 股該公司的股票。股票以平均價格 57.06 美元出售，總交易額為 41,824.98 美元。出售後，首席財務官現在直接持有 107,991 股該公司的股票，價值 6,161,966.46 美元。這代表其持股減少了 0.67%。該交易在向證券交易委員會的文件中披露，可以通過此鏈接訪問。此外，首席執行官 Reza Zadno 於 3 月 18 日星期二出售了 5,475 股該公司的股票。股票以平均價格 57.06 美元出售，總交易額為 312,403.50 美元。出售後，首席執行官現在直接持有 173,070 股該公司的股票，價值約 9,875,374.20 美元。該交易使其持股減少了 3.07%。該交易的披露可以在這裏找到。在過去三個月中，內部人士出售了價值 368,322 美元的 6,455 股公司股票。公司內部人士持有該公司 6.60% 的股份。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Why Intuitive Surgical Stock is Dominating the Medical Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 Intuitive Surgical 股票在醫療行業中佔據主導地位</li>
</ul>
</div><p>Several equities analysts have recently weighed in on the stock. Truist Financial decreased their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, April 11th. Bank of America decreased their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, April 25th. Wall Street Zen raised shares of PROCEPT BioRobotics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Finally, Morgan Stanley decreased their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an &#34;overweight&#34; rating on the stock in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $90.00.</p>
<div class="lb-trans"><p>幾位股票分析師最近對該股票發表了看法。Truist Financial 將 PROCEPT BioRobotics 的股票目標價從 90.00 美元下調至 70.00 美元，並在 4 月 11 日的研究報告中給予該股票 &#34;買入&#34; 評級。美國銀行將 PROCEPT BioRobotics 的股票目標價從 104.00 美元下調至 84.00 美元，並在 4 月 25 日的研究報告中給予該股票 &#34;買入&#34; 評級。Wall Street Zen 在週六的研究報告中將 PROCEPT BioRobotics 的股票評級從 &#34;賣出&#34; 上調至 &#34;持有&#34;。最後，摩根士丹利在 2 月 26 日的研究報告中將 PROCEPT BioRobotics 的股票目標價從 105.00 美元下調至 95.00 美元，並給予該股票 &#34;增持&#34; 評級。兩位分析師對該股票給予了持有評級，六位分析師給予了買入評級。根據 MarketBeat 的數據，該股票的共識評級為 &#34;適度買入&#34;，共識目標價為 90.00 美元。</p>
</div><p><strong>Check Out Our Latest Report on PROCEPT BioRobotics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 PROCEPT BioRobotics 的最新報告</strong></p>
</div><h2>PROCEPT BioRobotics Stock Performance</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 股票表現</h2>
</div><p>NASDAQ:PRCT opened at $57.38 on Tuesday. The company's 50-day moving average is $55.27 and its two-hundred day moving average is $70.16. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of -29.43 and a beta of 1.10. PROCEPT BioRobotics Co. has a 1-year low of $47.04 and a 1-year high of $103.81. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07.</p>
<div class="lb-trans"><p>NASDAQ:PRCT 週二開盤價為 57.38 美元。該公司的 50 日移動平均線為 55.27 美元，200 日移動平均線為 70.16 美元。該公司的市值為 31.7 億美元，市盈率為 -29.43，貝塔係數為 1.10。PROCEPT BioRobotics Co. 的一年低點為 47.04 美元，一年高點為 103.81 美元。該公司的債務與股本比率為 0.21，流動比率為 6.02，速動比率為 5.07。</p>
</div><p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. The business had revenue of $69.16 million for the quarter, compared to the consensus estimate of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business's revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.51) EPS. Analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics (NASDAQ:PRCT - 獲取免費報告) 最近於 4 月 24 日星期四發佈了季度財報。該公司報告季度每股收益（EPS）為 -0.45 美元，超出分析師的共識預期（-0.49 美元）0.04 美元。該業務的季度收入為 6916 萬美元，而共識預期為 6539 萬美元。PROCEPT BioRobotics 的淨利潤率為 -50.07%，股本回報率為 -38.57%。該業務的收入同比增長 55.5%。在去年同期，該公司每股收益為 -0.51 美元。分析師預測 PROCEPT BioRobotics Co. 今年將發佈 -1.75 美元的每股收益。</p>
</div><h2>About PROCEPT BioRobotics</h2>
<div class="lb-trans"><h2>關於 PROCEPT BioRobotics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).</p>
<div class="lb-trans"><p>PROCEPT BioRobotics Corporation 是一家外科機器人公司，專注於在美國和國際上開發變革性泌尿學解決方案。該公司開發、製造和銷售 AquaBeam 機器人系統，這是一種圖像引導的外科機器人系統，旨在用於微創泌尿外科手術，重點治療良性前列腺增生 (BPH)。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than PROCEPT BioRobotics</li>
<li>How to Calculate Inflation Rate</li>
<li>Workday Stock Price Implosion: An Automatic Buy for AI Investors</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>MercadoLibre Is Soaring—Should You Wait for a Better Entry?</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 PROCEPT BioRobotics</li>
<li>如何計算通貨膨脹率</li>
<li>Workday 股票價格暴跌：對 AI 投資者來説是自動買入</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>MercadoLibre 正在飆升——你應該等待更好的入場時機嗎？</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>對市場有疑慮？三隻股票幫助你度過恐懼、不確定性和懷疑</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PRCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in PROCEPT BioRobotics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 PROCEPT BioRobotics 嗎？</h2>
</div><p>Before you consider PROCEPT BioRobotics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 PROCEPT BioRobotics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在買入的股票，以便在更廣泛的市場注意到之前... 而 PROCEPT BioRobotics 並不在名單上。</p>
</div><p>While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 PROCEPT BioRobotics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Nuveen Asset Management LLC 出售了 PROCEPT BioRobotics Co.（NASDAQ: PRCT）的股份